Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| CYTOKINETICS INCCYTK · Entity 3528 | Director | May 27, 2026 | May 27, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,808 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 163,808 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
CYTOKINETICS INC
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,361 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,851 · Balance 26,361 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.15 · Expires 2036-05-26 | Direct | 4,301 |
Reported balance
After 2026-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-27 · Grant · Acquired 4,301 · Balance 4,301 |
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,403 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 36,403 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
VERACYTE, INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,718 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 1,864 · Balance 42,718 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2022 Filed May 3, 2022 01:49 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 11,700 | $0.00 Strike: $50.29 | $0.00 |
DisclosureSEC source: 0001209191-22-026561 · doc4.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires 2032-04-27 F2 · derivative.exercise_date: This option was granted on April 28, 2022 with respect to 11,700 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 28, 2023 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter. Read SEC document |
| April 28, 2022 Filed May 3, 2022 01:49 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 7,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026561 · doc4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,954 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 293 | $38.38 | $11,245.34 |
DisclosureSEC source: 0001061983-22-000086 · edgardoc.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,537 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $38.38, representing the Issuer's closing stock price on April 1, 2022. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 244 | $46.00 | $11,224.00 |
DisclosureSEC source: 0001061983-22-000008 · edgardoc.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,244 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $46.00, representing the Issuer's closing stock price on January 3, 2022. F2 · balance_after: Amount includes 244 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001061983-21-000136 · edgardoc.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-12 F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-21-000136 · edgardoc.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 20:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 11,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000055 · wf-form4_161653247749352.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,541 F1 · kind: Restricted stock units awarded on March 19, 2021 vest as to one-third (1/3) of the shares on each of the first, second and third annual anniversaries of the date of grant. F2 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 20:47 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 63,687 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001567619-21-006314 · doc1.xml · derivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,687 Underlying: Common Stock · 63,687 shares Expires 2031-03-11 F1 · derivative.exercise_date: The shares subject to the option vest in 36 successive, equal monthly installments on each monthly anniversary of March 11, 2021, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 01:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $21.86 Strike: $21.86 | $765,100.00 |
DisclosureSEC source: 0001061983-21-000030 · edgardoc.xml · derivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-02-17 F1 · derivative.exercise_date: Options shall vest and become exercisable in 36 equal monthly installments as from the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.